• Citer

Evaluation of PI3K-pathway–activation status in matched primary (P) and metastatic (M) ER+/HER2- breast cancer (BC) lesions according to PIK3CA-mutation status.

par Fumagalli, Debora ;Jose, Vinu ;Salgado, Roberto;Michiels, Stefan ;Wilson, TR;O'Brien, CO;HUW, L;Rouas, Ghizlane;Criscitiello, Carmen ;Pugliano, Lina ;Piccart-Gebhart, Martine ;Lackner, MR;Loi, Sherene ;Sotiriou, Christos
Référence ASCO Annual Meeting 2014 (May 30 - June 3, 2014: Chicago, Il, USA)
Publication Non publié, 2014

Poster de conférence

• Détails
• Contenu

Titre:	Evaluation of PI3K-pathway–activation status in matched primary (P) and metastatic (M) ER+/HER2- breast cancer (BC) lesions according to PIK3CA-mutation status.
Auteur:	Fumagalli, Debora; Jose, Vinu; Salgado, Roberto; Michiels, Stefan; Wilson, TR; O'Brien, CO; HUW, L; Rouas, Ghizlane; Criscitiello, Carmen; Pugliano, Lina; Piccart-Gebhart, Martine; Lackner, MR; Loi, Sherene; Sotiriou, Christos
Informations sur la publication:	ASCO Annual Meeting 2014 (May 30 - June 3, 2014: Chicago, Il, USA)
Statut de publication:	Non publié, 2014
Sujet CREF:	Cancérologie
	Médecine pathologie humaine
	Sciences bio-médicales et agricoles
Langue:	Anglais